Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04303780 · ClinicalTrials.gov registry record · Phase 3
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
A Phase 3 study of KRAS p, G12c Mutated /Advanced Metastatic NSCLC, sponsored by Amgen.
- Active
- Registry status
- Phase 3
- Development phase
- 345
- Enrollment target
- 20
- Study locations
NCT04303780 is a Phase 3 study of KRAS p, G12c Mutated /Advanced Metastatic NSCLC that is active but no longer recruiting, run by Amgen. The registered enrollment target is 345 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT04303780, a Phase 3 study of KRAS p, G12c Mutated /Advanced Metastatic NSCLC, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 345 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG AMG 510
Study Locations (20)
California
- Pacific Cancer Medical Center Inc - Anaheim
- City of Hope National Medical Center - Duarte
- Pacific Shores Medical Group Long Beach - Long Beach
- University of California Los Angeles - Los Angeles
- University of California Los Angeles - Los Angeles
- University of California at Davis Medical Center - Sacramento
- Ridley Tree Cancer Center - Santa Barbara
- University of California San Francisco Mission Hall - Stanford
- Harbor University of California Los Angeles Medical Center - Torrance
Florida
- Florida Cancer Specialists - Fort Myers - Fort Myers
- Memorial Regional Hospital - Hollywood
- Florida Cancer Specialists Research North - St. Petersburg
- Florida Cancer Specialists Research Panhandle - Tallahassee
Georgia
- Emory University - Atlanta
- Northside Hospital, Incorporated - Atlanta
Colorado
- Rocky Mountain Cancer Centers - Denver
Connecticut
- Danbury Hospital - Norwalk
Delaware
- Medical Oncology Hematology Consultants Helen F Graham Cancer Center - Newark
District of Columbia
- Washington Cancer Institute at MedStar Washington Hospital - Washington D.C.
Illinois
- Affiliated Oncologists, LLC - North Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2020-06-04 |
| Est. Completion | 2026-02-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04303780
The ClinicalTrials.gov registry entry for NCT04303780 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 345 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with KRAS p, G12c Mutated /Advanced Metastatic NSCLC appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.
NCT04303780 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT04303780 about?
NCT04303780 is a clinical study titled "Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).". A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation
What is the current status of trial NCT04303780?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 345 participants. The study started on 2020-06-04. Estimated completion is 2026-02-25.
What conditions does trial NCT04303780 study?
This clinical trial studies the following conditions: KRAS p, G12c Mutated /Advanced Metastatic NSCLC.
What interventions are being tested in trial NCT04303780?
The interventions under investigation include: Docetaxel (DRUG), AMG 510 (DRUG).
Who is sponsoring clinical trial NCT04303780?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04303780 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.